Becton, Dickinson and Company (BD) has reported a revenue of $5.1bn in the fourth quarter (Q4) of 2023, a 6.8% rise from $4.7bn in the corresponding period last year.

In the quarter, the company’s reported diluted earnings per share (EPS) from continuing operations were $0.53, a 42.4% decrease from the previous year’s $0.92.

The quarter’s adjusted diluted EPS was $3.42, an increase of 24.4% from $2.75 in the same period last year.

The company’s full-year revenue was $19.3bn, a 2.7% rise from the $18.87bn reported last year.

Its net income for the full year stood at $1.48bn, a 16.6% decrease from the $1.77bn reported in the corresponding period last year.

It anticipates revenues for the fiscal year 2024 (FY24) to fall between approximately $20.1bn and $20.3bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, BD expects that the adjusted diluted EPS for FY24 will range from $12.70 to $13.00, a growth rate of roughly 4% to 6.5%.

BD chairman, CEO and president Tom Polen said: “We achieved another quarter and another year of strong performance through our talented team’s execution of our BD2025 strategy and differentiated portfolio of medical technologies that are increasing healthcare efficiency and improving the lives of patients around the world.

“Looking ahead, continued execution of our category leadership strategy in higher-growth markets, advancement of our strong innovation pipeline and delivery against our simplification programmes position us well to deliver durable growth in FY24 and beyond.”